Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share

Author: Benzinga Newsdesk | August 15, 2024 03:00am

The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $300.1 million. The offering is expected to close on or about August 16, 2024, subject to the satisfaction of customary closing conditions.
Avidity intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the development of its clinical programs, to advance research and development associated with its AOC platform and for working capital and general corporate purposes.

Posted In: RNA